<DOC>
	<DOC>NCT00330889</DOC>
	<brief_summary>This study will assess the Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of Prednisolone on Rheumatoid Arthritis (RA) patients.</brief_summary>
	<brief_title>Effects Of Prednisolone On Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criteria: Meet the ACR criteria for diagnosis of rheumatoid arthritis. Required treatment with Prednisolone. Currently on a nonsteroidal antiinflammatory agent (NSAID). Willing to stay on current dose of NSAID for two weeks during study. Exclusion criteria: Major health issues such as osteoporosis, diabetes, heart failure, heart attack, kidney failure, or acute infection.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>